Preparation of ciprofloxacin-encapsulated poly(DL-lactide-co-glycolide) microspheres and its antibacterial activity

Journal of Pharmaceutical Sciences

Volumn 98, Issue 10, 2009, Pages 3659-3665

  Jeong, Young Il ^a   Na, Hee Sam ^b   Nah, Jae Woon ^a   Lee, Hyun Chul ^b  

^a Department of Polymer Science and Engineering ^*  (South Korea)

^b Chonnam National University Medical School   (South Korea)

Author keywords

Ciprofloxacin HCl; Infection model; Microsphere; Poly(DL lactide co glycolide); Sustained release

Indexed keywords

CIPROFLOXACIN; RESOMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBACTERIAL ACTIVITY; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; DRUG HALF LIFE; DRUG SYNTHESIS; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MICROENCAPSULATION; MOUSE; NONHUMAN; PARTICLE SIZE; SALMONELLA TYPHIMURIUM; SALMONELLOSIS; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE;

EID: 70349251261     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21680     Document Type: Article

References (14)

1. Emmerson AM. 1989. The role of the skin in nosocominal infection: A review. J Chemother 1:12-18.
2. Appelbaum PC, Hunter PA. 2000. The fluoroquinolone antibacterials: Past, present, and future perspective. Int J Antimicrob Agents 16:5-15. (Pubitemid 30665419)
3. Stratton C. 1992. Fluoroquinolone antibiotics: Properties of the class and individual agents. Clin Ther 14:348-375.
4. Davis R, Markham A, Balfour JA. 1996. Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy, and tolerability. Drugs 51:1019-1074.
5. Naber KG, Bergman B, Bishop MC. 2001. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 40:576-588.
6. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. 1999. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Disease Society of America (IDSA). Clin Infect Dis 29:745-758. (Pubitemid 30256361)
7. Ma Z, Ma L, Gao C, Shen J. 2005. Preformed microcapsules for loading and sustained release of ciprofloxacin hydrochloride. J Control Release 104:193-202. (Pubitemid 40615246)
8. Page-Clisson ME, Pinto-Alphandary H, Ourevitch M, Andremont A, Couvreur P. 1998. Development of ciprofloxacin-loaded nanoparticles: Physicochemical study of the drug carrier. J Control Release 56:23-32. (Pubitemid 28511123)
9. Talan DA, Naber KG, Palou J, Elkharrat D. 2004. Extended-release ciprofloxacin (Cipro XR) for treatment of urinary tract infections. Int J Antimicrob Agents 23(Suppl 1):S54-S66. (Pubitemid 38376050)
10. John Threlfall E. 2002. Antimicrobial drug resistance in Salmonella: Problems and perspectives in food- and water-borne infections. FEMS Microbial Rev 26:141-148.
11. 15 National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. 6th edition. Approved Standard M7-A6. Wayne, PA, USA: NCCLS.
12. Dillen K, Vandervoort J, Van den Mooter G, Verheyden L, Ludwig A. 2004. Factorial design, physicochemical characterisation and activity of ciprofloxacin-PLGA nanoparticles. Int J Pharm 275:171-187. (Pubitemid 38481530)
13. Dillen K, Vandervoort J, Van den Mooter G, Ludwig A. 2006. Evaluation of ciprofloxacin-loaded Eudragit RS100 or RL100/PLGA nanoparticles. Int J Pharm 314:72-82.
14. Arnold MM, Gorman EM, Schieber LJ, Munson EJ, Berkland C. 2007. NanoCipro encapsulation in monodisperse large porous PLGA microparticles. J Control Release 121:100-109. (Pubitemid 47126070)